FGF21 ELISA

The FGF19 subfamily composed of FGF15/19, FGF21 and FGF23 binds the FGF receptors co-joined by α- or β-Klotho and it is characterized as a factor group which has hormonal functions. The novel system consisted of α/βKlotho and FGF19 subfamily regulates integrally metabolism of minerals, lipids, energy and amino acids. This novel regulating system involves important homeostatic mechanisms in the body such as bile acid and cholesterol metabolism in the liver (through FGF19), energy and glycolipids metabolism (through FGF21) and phosphate, calcium and vitamin D metabolism in kidney (through FGF23) in fasting state. FGF21 is secreted in the liver and it is responsible for glucose uptake of adipocytes. FGF21 binds to a receptor unit consisting of FGFR and β-Klotho. It has been shown that treating animals with FGF21 leads to increased energy expenditure, fat utilization and lipid excretion meaning a decrease of glucose and triglyceride levels in blood. FGF21 levels in blood correlate with many diseases like gestational diabetes mellitus, mitochondrial dysfunction in HIV infection, friedreich ataxia, coronary artery disease, carotid atherosclerosis, non-alcoholic fatty liver disease, rheumatoid arthritis, diabetic nephropathy, type2 diabetes, dyslipidemia, obesity and metabolic syndrome. This kit measures FGF21 levels in serum, EDTA plasma and cell culture supernatants. Separate control set available on request Distributed by IBL International